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OBJECTIVES: We aimed to develop and validate the Reﬂux Symptom Questionnaire electronic Diary (RESQ-eD) for use in
clinical trials inpatients with a partial response to proton pump inhibitor (PPI) therapy, using methods that meet US Food & Drug
Administration (FDA) regulatory standards.
METHODS: Patient interviews were performed to elicit new items and evaluate existing items from the Reﬂux Disease Questionnaire.
The instrument’s measurement properties were evaluated, based on data from two clinical trials of patients with gastroesophageal
reﬂux disease (GERD) with a partial response to PPIs who received lesogaberan or placebo as an add-on to PPI therapy.
RESULTS: The content validity phase resulted in 13 RESQ-eD items. Principal component analysis supported a four-domain
structure. All domains had a high inter-item correlation (Cronbach’s alpha lower 95% conﬁdence limit: 0.87–0.95). Test-retest
reliability was good to excellent (intraclass correlation coefﬁcient: 0.65–0.85). Convergent and discriminant validity was
conﬁrmed by correlation assessments referencing the Gastrointestinal Symptom Rating Scale. The RESQ-eD demonstrated a
good ability to capture change in mean intensity and proportion of symptom-free days. Conﬁrmatory psychometric evaluation
veriﬁed internal consistency reliability, test-retest reliability, and ability to capture change.
CONCLUSIONS: The RESQ-eD demonstrated good content validity and psychometric properties in the clinical trial setting in
patients with GERD who have a partial response to PPI therapy. To our knowledge, the RESQ-eD is the ﬁrst electronic symptom
diary for use in partial responders to PPI that has been developed in line with the FDA guidance on patient-reported outcomes.
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INTRODUCTION
Most patients with gastroesophageal reﬂux disease (GERD)
experience resolution of their heartburn and regurgitation
when on proton pump inhibitor (PPI) therapy.
1,2 However,
a recent systematic review showed that, in interventional
primary care trials, approximately 20–30% of patients with
GERD experience only a partial response of their heartburn or
regurgitation symptoms to PPI therapy.
3 Potential pharmaco-
logical targets in the treatment of partial response to PPI
therapy include esophageal mechanisms of visceral sensiti-
vity and nociception, and inhibition of transient lower
esophageal sphincter relaxations (TLESRs).
3–6 Other thera-
peutic approaches to partial response to existing medications
include more potent or longer acting acid inhibitors. Using
esophageal impedance-pH monitoring, clinical trials in
patients with GERD and in healthy volunteers have shown
that the reﬂux inhibitor lesogaberan (AZD3355) reduces the
numbers of TLESRs, increases lower esophageal sphincter
pressure and decreases the number of reﬂux episodes.
7,8
However, the majority of reﬂux episodes that are detected
using impedance-pH monitoring are asymptomatic and the
role of new therapeutic approaches in partial responders
to PPIs is uncertain.
9,10
GERD is a symptom-driven disease that has to be
evaluated based on the presence, frequency, and severity
of GERD symptoms.
11 These are best captured and mea-
sured using patient-reported outcome (PRO) instruments.
The US Food and Drug Administration (FDA) recently
published its guidance for industry on the use of PRO
instruments in medical product development to support
labelling claims.
12 The guidance emphasizes the importance
of obtaining evidence of the relevancy (i.e., content validity) of
the PRO instrument from the target patient population, and of
ensuring that the population studied in the PRO instrument
development and documentation process is comparable with
that in the clinical study setting in which the instrument is to
be used (i.e., that the instrument is ‘‘ﬁt for purpose’’).
The FDA guidance calls for patient input during the
development of PRO instruments and establishment of
their content validity.
12 To assess content validity of a PRO
instrument, the FDA intends to review the derivation of
items, transcripts from focus groups and cognitive interviews,
and the composition of patient groups involved in content
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www.nature.com/ctgdevelopment. Additional measurement properties that will
needtobeestablishedareinternalconsistencyandtest-retest
reliability, convergent and discriminant validity, known-groups
validity, and responsiveness to change. Furthermore,
the FDA guidance encourages planning for clinical trial
interpretation using an a priori responder deﬁnition.
Several instruments have undergone psychometric evalua-
tion in patients with GERD for use in clinical practice and
in clinical trials. One of the most extensively evaluated
instruments in GERD is the Reﬂux Disease Questionnaire
(RDQ).
13–15 However, neither the RDQ nor, as far as we
know, any other PRO instrument has been developed for the
speciﬁc target population of patients with GERD with a partial
response to PPI therapy. Consequently, these instruments
maynot capturethecomplete symptompatternofthis speciﬁc
group of patients. This paper describes how methodology
outlined in recent regulatory guidelines was applied in the
development and psychometric evaluation of a new PRO
instrument, the Reﬂux Symptom Questionnaire electronic
Diary (RESQ-eD), intended for use in clinical trials in patients
with a partial response to PPI therapy. The RDQ was used as
a basis for the development of the RESQ-eD.
METHODS
RESQ-eD development. The RESQ-eD was developed in
two stages: (i) patient interviews were performed to elicit new
items and to evaluate existing items from the RDQ (content
validity); and (ii) evaluation of the instrument’s measurement
properties (including reliability, validity, and responsiveness)
were performed. Both of these stages included an
exploratory and a conﬁrmatory phase.
Exploratory interview study: exploratory content validity
phase. Eighty patients diagnosed with GERD, or having
GERD according to their physician’s judgement, participated
in an independent interview study in the USA, France, and
Japan. All patients had remaining symptoms of heartburn
and/or regurgitation despite continuous PPI therapy during
the previous 6 weeks. Patients were identiﬁed through
a commercial recruitment agency that enlisted gastro-
enterologists and primary care physicians to help with recruit-
ment. The age range was 25–85 years, and 50 (63%)
patients were women. Patients were excluded if they had
lower gastrointestinal symptoms consistent with those of
irritable bowel syndrome or if they had a history of, or current,
peptic ulcer disease. Symptom concepts relevant to partial
responders to PPI therapy were elicited in four languages
(US English, US Spanish, French, and Japanese). Semi-
structured guides that contained a series of open-ended
questions in 48 individual interviews and four focus group
interviews (32 patients) were used. Patient statements
were coded to identify relevant symptom concepts, and
saturation of concepts was measured. Concept selection and
conﬁrmation were guided by expert opinion (one US and one
Australian gastroenterologist) and a review of published
GERD studies, including observational studies, clinical trials,
and instrument development and validation studies.
PRO Validation Study: conﬁrmatory content validity
phase and exploratory psychometric validation phase.
The PRO Validation Study (ClinicalTrials.gov identiﬁer:
NCT00703534) was conducted between May and December
2008 at 77 centers in the USA. The aim of the study was to
evaluate prospectively the domain structure performance of
the instrument in the target patient population. The study had
a randomized, double-blind, placebo-controlled, parallel-group
design consisting of an 8–12-day screening phase (part 1),
followed by randomization into a 4-week treatment phase
(part 2). As an add-on to PPI therapy (see below), patients
received either lesogaberan 65mg twice daily or matching
placebo.
Overall, 580 patients were eligible for part 1 (mean age: 48
years [range: 19–70]; 58% women), and 478 patients from
part1werefurtherrandomizedintopart2(meanage:49years
[range: 19–70]; 59% women). Patients were eligible for
inclusion if they had a history of GERD symptoms for at least
6 months and had received a minimum of 4 weeks of
PPI therapy (8 weeks of treatment if diagnosed with
reﬂux esophagitis within the previous 8 weeks), individually
optimized according to the physician’s judgement, within the
approved dose range for any GERD indication. Patients
whose symptoms did not improve at all after PPI therapy
were excluded from the study. For enrollment into part 1 and
randomizationintopart2,patientsshouldhaveexperiencedat
least 3 days of a burning feeling behind the breastbone and/or
unpleasant movement of material upwards from the stomach
over the previous 7 days; symptoms had to be of at least
mild intensity (score Z2 on a 6-point scale ranging from 0 [did
not have] to 5 [severe]). For inclusion into part 1, symptoms
were assessed with an instrument with the same items
as the RESQ-eD, but with a 7-day recall period (RESQ-7).
For inclusion into part 2, the RESQ-eD was used. Patients
were required to complete the RESQ-eD twice daily (morning
and before bedtime) during the study period to assess
symptom intensity (ranging from 0 [did not have] to 5
[severe]). In addition, patients were requested to complete
the Gastrointestinal Symptom Rating Scale (GSRS) at
enrollment and at randomization, and the Overall Treatment
Evaluation (OTE) 2 weeks and 4 weeks after randomization,
including an evaluation of the importance of perceived
change.
Conﬁrmatory individual interviews were conducted with
42 of the patients included in the PRO Validation Study,
to conﬁrm the relevance of the symptom items that were
generated during the exploratory interview study. Patients
had been asked at enrolment at participating clinical sites
whether they would be interested in taking part in two
interviews about their experience with GERD in addition to
the other study procedures. The draft instrument at this point
contained 13 symptoms to be rated on a 6-point scale ranging
from0to5.Cognitiveinterviewswereperformedafterpatients
had completed the RESQ-eD twice daily for about 1 week.
Spontaneous reports of symptoms were noted, and patients
were also asked whether symptoms measured in the study
were relevant to their GERD experience. As part of the
individual interviews, patients were also asked about their
treatment expectations before their treatment commenced,
and were asked about the importance and meaningfulness
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treatment.
Lesogaberan Dose-ﬁnding Study—conﬁrmatory psycho-
metric validation phase. Psychometric evaluation of the
RESQ-eD was conﬁrmed in the lesogaberan Dose-ﬁnding
Study (ClinicalTrials.gov identiﬁer: NCT01005251), which
was conducted between October 2009 and July 2010 at
multiple centers in the USA, Canada, and Europe. The study
had a randomized, double-blind, placebo-controlled, parallel-
group design consisting of an 8–26-day screening phase,
followed by randomization into a 4-week treatment phase.
Patient inclusion and exclusion criteria were the same as for
the PRO Validation Study (described above), except that
symptoms for enrollment and randomization had to be of
at least moderate intensity (score Z3 on a 6-point scale
ranging from 0 [did not have] to 5 [severe]) and PPI treat-
ment had to be within the GERD label for the country of
the enrolling site. In addition to the USA and Canadian
English language versions, the following language versions
of the RESQ-eD were translated and linguistically validated
using procedures recommended by the International
Society for Pharmacoeconomics and Outcomes Research
Task Force for Translation and Cultural Adaption,
16 including
forward/backward translation and cognitive debrieﬁng:
French (France and Canada), German, Hungarian,
Romanian, Spanish (USA), Latvian, and Russian (Latvia).
In total, 661 patients were randomized in the lesogaberan
Dose-ﬁnding Study (mean age: 48 years [range: 18–70
years]; 57% women). Most (n¼504; 76.2%) participants
were from the USA. Patients were required to complete the
RESQ-eD twice daily (morning and before bedtime) during
the study period, and to complete the OTE 2 weeks and
4 weeks after randomization.
Reference measures for validation
Overall Treatment Evaluation. The OTE is an instrument
that rates the magnitude and importance of changes in
symptoms on a 15-point scale.
17,18 For magnitude of change,
patients were grouped as follows: ‘‘worse’’ (score: –7 to –2);
‘‘unchanged’’ (score: –1, 0, þ1); ‘‘small improvement’’ (score:
þ2, þ3); ‘‘moderate improvement’’ (score: þ4, þ5); and
‘‘large improvement’’ (score: þ6, þ7). For importance of
change, patients were grouped as follows: ‘‘deterioration of
any importance’’ (score: –7 to –2); ‘‘no important change’’
(score: –1, 0, þ1); ‘‘improvement of small importance’’ (score:
þ2, þ3); ‘‘improvement of moderate importance’’ (score: þ4,
þ5); and ‘‘improvement of large importance’’ (score: þ6, þ7).
The OTE is derived from the Global Ratings of Change
Questionnaire.
19,20
Gastrointestinal Symptom Rating Scale. The GSRS is an
instrument with a 1-week recall that assesses symptom
severity using a 7-grade Likert scale, ranging from 1 (‘‘no
discomfort at all’’) to 7 (‘‘very severe discomfort’’).
21 The
instrument consists of 15 items that are clustered into ﬁve
domains: Reﬂux, Abdominal pain, Indigestion, Diarrhea, and
Constipation. Of relevance to the present Validation Study,
the Reﬂux domain consists of heartburn and regurgitation
items, and the Indigestion domain includes an item for
burping. Based on percentiles from previous data in order to
get three groups of similar size, GSRS domain scores
(derived as the mean of the separate item scores) were
grouped as follows: ‘‘low’’ (score: r4.0); ‘‘medium’’ (score:
44.0 and r5.0); and ‘‘high’’ (score: 45.0).
Statistics. Statistical analyses were performed using SAS
s
version 8.2 (SAS Institute Inc., Cary, NC, USA). Unless
otherwise stated, psychometric properties of the RESQ-eD
were evaluated in the 7 days before randomization, (i.e.,
before the start of treatment). Psychometric evaluation of the
RESQ-eD was performed on data irrespective of treatment.
Calculation of variables. Missing values were imputed if the
length of the gap was one registration in the sequence
of morning and bedtime registrations respectively, in which
case the value was imputed as the maximum of the
two surrounding values in the respective sequence. Daily
intensity values were then derived as the maximum of a
bedtime value and the following morning value, but set to
missing if one of the two values were still missing after
imputation of morning and bedtime registrations. Mean
intensity over a time period was then calculated unless the
proportion of daily values missing was greater than 30%. In
calculations of proportion of days without symptoms or
symptoms above a certain intensity, a day with missing
values was regarded as a day with symptoms above the
given threshold. RESQ-eD domain intensity scores were
derived as the mean value of the item intensity scores within
the domain.
Principal component analysis. Principal component analysis
with varimax and oblimin rotation was performed on variables
of intensity and frequency of symptoms (mean intensity and
number of days with symptoms, respectively) to identify
items that correlate strongly enough to form homogeneous
domains.
Reliability. Internal consistency (i.e., to what extent items
within a domain are interrelated) was evaluated using
Cronbach’s alpha coefﬁcients. Cronbach’s alpha is a
measure of reliability and an alpha value 40.7 was consi-
dered as supporting internal consistency reliability.
22 Test-
retest reliability (i.e., the stability of an instrument over time)
was assessed between randomization and 2 weeks after
randomization, using intraclass correlation coefﬁcients (ICC)
in patients considered to be in a stable condition (‘‘unchanged’’
according to the OTE classiﬁcation). ICC values of 0.4–0.75
were considered to represent fair to good reliability and values
40.75 represented excellent reliability.
23
Construct validity. Spearman’s rho was used to evaluate
convergent and discriminant validity. Convergent validity
refers to how well constructs that theoretically should be
related to each other are observed to be related. Discriminant
validity can be viewed as the counterpart to convergent
validity and is based on the assumption that constructs
theoretically not related to each other are not observed to be
related to each other and therefore demonstrate low
correlations. The GSRS domains and single item ‘‘burping’’
RESQ-eD: Validation in Partial Responders
Vakil et al.
3
Clinical and Translational Gastroenterologywere used as references for these assessments. Known-
groups validity (i.e., an instrument’s ability to differentiate
between groups of patients known to be clinically distinct)
was evaluated graphically using the GSRS reﬂux domain and
burping item scores to separate patients into subgroups by
symptom severity.
Responsiveness to change. The instrument’s responsive-
ness to change was evaluated by graphical depiction of the
effect size using the variables intra-patient change in mean
domain intensity from baseline (the 7 days before randomi-
zation) to the treatment period (approximately 4 weeks
treatment) and the intra-patient change in proportion of
symptom-free days from baseline to treatment period. The
effect size was deﬁned as the mean individual change over
time divided by the standard deviation at baseline, and was
calculated on subgroups of patients determined by the OTE
classiﬁcations at the end of treatment.
Ethical considerations. The studies were performed in
accordance with the Declaration of Helsinki and the
International Conference on Harmonisation Good Clinical
Practice guide. The study protocol was approved by a
central, free-standing board—the Schulman Associates
Institutional Review Board—prior to patient enrollment. All
patients included in the analysis gave their written informed
consent prior to participation.
RESULTS
Exploratory interview study: exploratory content validity
phase. During the exploratory interviews, all six symptom
expressions from the RDQ were mentioned by at least
20 patients (Table 1). Six additional symptom expressions
emerged from the interviews: heartburn, difﬁculty swallowing,
cough, nausea, hoarseness, and burping. ‘‘Bitter taste in
mouth’’ was mentioned by fewer than 20 patients, but was
deemed relevant based on empirical evidence and expert
input. ‘‘Stomach contents (liquid or food) moving upwards
towards your throat or mouth’’ was added, based on patient
and expert input, to specify the location of regurgitation. All
expressions, except nausea, which was deemed too non-
speciﬁc, were included in the RESQ-eD. All RDQ items were
retained. Literature searches and expert opinion conﬁrmed
the proposed 13 RESQ-eD items as relevant. Furthermore,
a vast majority of the interviewed patients had no difﬁculty
understanding the instructions or response options. The
exploratory content validity phase therefore resulted in 13
items. Items were scored for intensity on a 6-point scale
(0¼did not have; 1¼very mild; 2¼mild; 3¼moderate;
4¼moderately severe; 5¼severe).
PRO Validation Study: conﬁrmatory content validity
phase and exploratory psychometric validation phase
Conﬁrmatory interviews. Individual interviews conﬁrmed the
relevance of the symptom items of the RESQ-eD. Patients
collectively reported all symptoms included in the RESQ-eD,
and endorsed all items as being relevant to their experience
of GERD. The majority (86%) of patients understood all
13 items of the RESQ-eD and did not make suggestions for
modiﬁcations. Before treatment, 53% of responses from the
patients indicated that any improvement in GERD symptoms
would be considered important and meaningful; following
treatment, 91% (29/32) of interviewed patients who had any
improvement in their GERD symptoms expressed that the
change was both important and meaningful.
Principal component analyses. In the principal component
analyses using varimax and oblimin rotation, an overall
evaluation of scree-plots, eigenvalues, and proportion of the
total variance accounted for suggested retaining two or three
components for rotation (Table 2).
Also, the three-factor solution was conceptually appealing
whenreviewing the rotated factor pattern. Taken together, the
principal component analysis and prior assumptions con-
verged in suggesting that a three-component solution may be
appropriate. The highest factor loading for the item burping
was found in the component with regurgitation items. How-
ever, the loadings of burping were not of the same magnitude
as the loadings of the other items in that component.
A four-domain structure was thus deemed most suitable for
the 13 items of the RESQ-eD, consisting of Heartburn (5
items: burning feeling, breastbone; pain, breastbone; heart-
burn; burning feeling, upper stomach; pain, upper stomach),
Regurgitation (4 items: acid taste in mouth; bitter taste in
mouth; unpleasant movement of material; stomach contents,
liquid or food), Hoarseness, cough, difﬁculty swallowing (3
items), and Burping (1 item). Subsequent analyses of
reliability, validity, and responsiveness of the RESQ-eD were
conducted on the four symptom domains.
Frequency tabulation analyses of the number of days with
RESQ-eD symptoms by domain in the 7 days before
randomization showed that 95% of enrolled eligible patients
had Heartburn, 90% had Regurgitation, 77% had Hoarse-
ness, cough, or difﬁculty swallowing, and 90% had Burping for
5–7 days during the week. All 13 items were also combined
into an Overall symptoms domain showing that 100% of
Table 1 The 13 items of the Reﬂux Disease Questionnaire electronic Diary
RESQ-eD item Item
retained
from RDQ
New item
added to
RESQ-eD
Burning feeling behind the breastbone |
Pain, breastbone |
Heartburn |
Acid taste in the mouth |
Bitter taste in the mouth |
Unpleasant movement of material upwards
from the stomach
|
Stomach contents (liquid or food) moving
upwards towards your throat or mouth
|
Burning feeling in the center of the upper
stomach
|
Pain in the center of the upper stomach |
Hoarseness |
Cough |
Difﬁculty swallowing |
Burping |
RDQ, Reﬂux Disease Questionnaire; RESQ-eD, Reﬂux Disease Questionnaire
electronic Diary.
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the week.
Reliability. All symptom domains of the RESQ-eD had a high
inter-item correlation, with the lower 95% conﬁdence limit
of Cronbach’s alpha in the range 0.87–0.95, indicating
high internal consistency reliability (Table 3). The RESQ-eD
showed good to excellent test-retest reliability for all domains
(Table 3).
Construct validity. The RESQ-eD burping item correlated
highly with both the GSRS burping item and Indigestion
domain (Table 4). The RESQ-eD Heartburn, Regurgitation,
and Overall symptoms domains showed high correlations
with the GSRS Reﬂux domain. The lowest correlations were
observed between all RESQ-eD domains and the GSRS
Diarrhoea and Constipation domains, thus supporting the
discriminant validity of the RESQ-eD. Increasing GSRS
scores were associated with increased symptom intensity in
all RESQ-eD domains and in the RESQ-eD burping item,
thus supporting the known-groups validity of the RESQ-eD
(Figure 1).
Responsiveness to change. The RESQ-eD demonstrated
good ability to capture change in mean intensity (Figure 2a)
and proportion of symptom-free days (Figure 2b). However,
no discrimination was observed between small and moderate
improvements.
Table 2 Principal component analysis of the mean intensity and frequency of symptoms in the Reﬂux Disease Questionnaire electronic Diary during the 7 days prior
to randomization (all enrolled eligible patients, N¼580)
RESQ-eD item Intensity Frequency
Factor 1 Factor 2 Factor 3 Factor 1 Factor 2 Factor 3
Burning feeling, breastbone 86 27 24 13 89 11
Pain, breastbone 83 25 27 19 77 18
Heartburn 82 35 18 16 84 0
Acid taste in mouth 34 80 31 79 24 26
Bitter taste in mouth 33 79 34 79 21 27
Unpleasant movement of material 35 82 29 88 19 19
Stomach contents, liquid or food 33 82 30 86 17 16
Burning feeling, upper stomach 77 39 24 35 71 18
Pain, upper stomach 75 40 27 43 62 26
Hoarseness 23 30 85 21 18 86
Cough 23 27 83 15 9 84
Difﬁculty swallowing 32 34 76 34 15 74
Burping 44 60 24 52 25 12
RESQ-eD, Reﬂux Disease Questionnaire electronic Diary.
Table 3 Internal consistency and test-retest reliability of the Reﬂux Disease Questionnaire electronic Diary
PRO Validation Study Dose-ﬁnding Study
Domain Cronbach’s alpha
(95% CI) (n¼580)
ICC (95% CI)
(n¼126)
Cronbach’s alpha
(95% CI) (n¼625)
ICC (95% CI)
(n¼188)
Heartburn 0.94 (0.94–0.95) 0.65 (0.54–0.74) 0.93 (0.92–0.94) 0.80 (0.75–0.85)
Regurgitation 0.95 (0.94–0.96) 0.74 (0.65–0.81) 0.89 (0.88–0.91) 0.81 (0.75–0.85)
Hoarseness, cough, difﬁculty swallowing 0.89 (0.87–0.91) 0.85 (0.79–0.89) 0.85 (0.83–0.87) 0.85 (0.81–0.89)
Burping NA 0.73 (0.63–0.8) NA 0.77 (0.70–0.82)
Overall symptoms 0.96 (0.95–0.96) 0.75 (0.66–0.82) 0.93 (0.92–0.93) 0.81 (0.75–0.85)
CI, conﬁdence interval; ICC, intraclass correlation coefﬁcient; NA, not applicable (single item domain); PRO, patient-reported outcome.
Table 4 Correlation between Reﬂux Disease Questionnaire electronic Diary and Gastrointestinal Symptom Rating Scale domains/items (all enrolled eligible
patients, N¼580)
RESQ-eD domain
a PRO Validation Study GSRS domain/item
b
Reﬂux Abdominal pain Indigestion Diarrhoea Constipation Burping
Heartburn 0.60 0.57 0.52 0.28 0.36 0.37
Regurgitation 0.64 0.50 0.48 0.28 0.32 0.35
Hoarseness, cough, difﬁculty swallowing 0.44 0.49 0.42 0.29 0.34 0.28
Burping 0.52 0.47 0.68 0.27 0.32 0.71
Overall symptoms 0.66 0.60 0.58 0.33 0.39 0.43
aWeekly RESQ-eD intensity score of the 7 days before randomization.
bReported at randomization. GSRS, Gastrointestinal Symptom Rating Scale;
PRO, patient-reported outcome; RESQ-eD, Reﬂux Disease Questionnaire electronic Diary.
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metric validation phase. Frequency tabulation of the
number of days with RESQ-eD symptoms by domain in the
7 days before randomization in the lesogaberan Dose-ﬁnding
Study showed that 100% of randomized patients had Overall
symptoms on 5–7 days during the week, 99% had Heartburn,
98% had Regurgitation, 88% had Hoarseness, cough, or
difﬁculty swallowing, and 95% had Burping.
Reliability. High inter-item correlations were observed for all
symptom domains of the RESQ-eD, thus conﬁrming high
internal consistency reliability observed in the PRO Valida-
tion Study (Table 3). Intraclass correlation coefﬁcients
conﬁrmed the good to excellent test-retest reliability for all
domains of the RESQ-eD (Table 3).
Responsiveness to change. The RESQ-eD demonstrated
good ability to capture change in intensity in all domains in
the lesogaberan Dose-ﬁnding Study, including an ability to
discriminate between small and moderate improvements
(Figure 3), thus conﬁrming its responsiveness to change.
DISCUSSION
The RESQ-eD was deemed to be valid, reliable, and
responsive to change in the clinical trial setting in partial
responders to PPI therapy. The 13 items of the RESQ-eD
were shown to measure the symptoms most relevant to the
target population, and can be meaningfully combined into an
Overall symptom domain and four separate domains (Heart-
burn; Regurgitation; Hoarseness, cough, and difﬁculty swal-
lowing; and Burping). Although a tool exists for use in clinical
practice,
24 the RESQ-eD is, to our knowledge, the ﬁrst
electronic symptom diary designed for use in clinical trials in
partial responders to PPI therapy, and has been developed
and documented in line with the FDA guidance on the
development and use of PRO instruments.
12 The RESQ-eD
is available in the public domain and is free for use in the
non-commercial setting, which is in keeping with GERD trial
design consensus recommendations on better access to
PROs.
25 A version of the instrument, with the same items, but
with a 7-day recall period (RESQ-7), is also available. Daily
symptom recording is the preferred method of capturing
patients’ symptom experience in the clinical trial setting and
the RESQ-7 may be more appropriate for use in routine
clinical care.
In accordance with the FDA guidance,
12 it was ﬁrst
determined through a systematic literature search that no
adequate PRO instrument exists for use in clinical trials of
patientson PPI therapywith persistentGERD symptoms. The
RDQ was then used as a basis for developing the RESQ-eD,
in line with the FDA guidance, which stipulates that if no
adequate instrument exists, then a new instrument can be
developed or modiﬁed from an existing instrument. The RDQ
is one of the most extensively used instruments in GERD, and
a paper-based version with a 7-day recall period has been
psychometrically evaluated in patients with GERD for use in
clinical trials and clinical practice.
13–15 However, the content
validity of the RDQ has not been established, nor has it been
evaluatedinpatientpopulationswithapartialresponsetoPPI,
whose symptom pattern may differ from those with complete
response or no response. The format (i.e., electronic diary)
and recall period of the RESQ-eD also differ from those of the
RDQ. The FDA guidance emphasizes the importance of
establishing content validity (that the instrument captures
everything relevant to measure what is intended) before other
measurement properties are evaluated, as evidence of other
types of validity will not overcome problems with content
validity.
The content validity of the RESQ-eD was evaluated in the
independent interview study and in the patient interviews in
the PRO Validation Study. The interviews reinforced the
relevance for the target patient population of the six RDQ
items. However, the exploratory interviews indicated that
relevant symptoms were missing. Therefore, seven more
items were extracted from the interviews and from expert
input, and included in the RESQ-eD. In the principal
component analysis of the RESQ-eD, the two dyspepsia
items in the original RDQ (i.e., pain and burning feeling in the
center of the upper stomach) clustered with those for
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Clinical and Translational Gastroenterologyheartburn,andwerethusincludedin theHeartburndomain.In
another study evaluating upper gastrointestinal symptoms,
epigastric pain and burning have shown what could be
perceived as inconsistent associations, where these symp-
tomshaveclusteredintheheartburnorthedyspepticdomains
depending on whether patients were classiﬁed as heartburn
predominant or non-heartburn predominant.
15 One explana-
tion for this perceived inconsistency may be that various
underlying mechanisms, such as reﬂux or dysmotility, gen-
erate epigastric symptoms.
26
Whenevaluatingsymptomsastheprimaryefﬁcacyvariable
in a disease where symptoms are ﬂuctuating, daily symptom
recording is likely to be the most reliable method of capturing
patients’ symptom experience. The FDA guidance notes that
items with short recall periods or items that ask patients to
describe their current or recent state are preferable to those
with longer recall periods; PRO instruments that call for
patients to rely on memory are likely to undermine content
validity.
12 Daily recording in an electronic diary may be
superior to questionnaires when data are to be recorded
contemporaneously, and has been shown previously to be
well suited to capturing symptoms that ﬂuctuate over time and
to facilitate calculation of symptom-free days.
27 Electronic
devices for data entry also help avoid prospective and
retrospective diary entry and associated recall bias.
No general European regulatory recommendations cur-
rently exist for PRO instrument development and docu-
mentation. However, in its section on PRO instruments, the
European Medicines Agency (EMA) draft guidelines on drug
evaluation recommend that fully validated GERD-speciﬁc
instruments should be used that focus on symptoms only
when quantifying symptoms to assess the efﬁcacy of drug
candidates; assessment of health-related quality of life should
be kept separate from symptom assessment.
28 The EMA
recommendations also advise that symptom evaluation
should include frequency and severity of symptoms, and that
both heartburn and regurgitation should be included,
28 all of
which apply to the RESQ-eD.
Several aspects of this study deserve comment. This is,
to our knowledge, the ﬁrst study that demonstrates the
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Clinical and Translational Gastroenterologyfeasibility of instrument development using new regulatory
and research standards for symptom assessments in
GERD. Our study provides the basis for the evaluation
of new drugs in the treatment of patients with GERD who
have an incomplete response to acid suppressive therapy.
The instrument has been designed to meet regulatory
expectations. However, for future use in clinical trials with
the goal of establishing labeling language based on the
RESQ-eD, it will be important to ensure that the content
of the instrument matches any future claims. In addition,
responder deﬁnitions for the instrument need to be explored
in the context of the patient population and the intended
claims.
As for a general GERD population, heartburn and regur-
gitation are the cardinal symptoms for partial responders.
However, this validation study also demonstrates that there
are other symptoms that need consideration in this patient
population, including cough, hoarseness, and burping. These
symptoms are associated with GERD syndromes but are not
measured with most instruments used in untreated GERD.
Studies have indicated that all or some of these additional
symptoms may also be relevant for a general GERD
population.
29–32 Therefore, it could be of interest for future
studies to evaluate the validity (content and psychometrical)
of the RESQ-eD also in a treatment naı ¨ve GERD population
including PPI responders.
In conclusion, the RESQ-eD demonstrated good content
validity and psychometric properties in the clinical trial setting
in patients with GERD who have a partial response to
optimized PPI therapy, as characterized by persistent GERD
symptoms. The RESQ-eD was validated in studies with
lesogaberan; however, it could be applicable for use in the
studyofotherdevelopmentalcompoundsthatmaybeusedas
treatment for the same target patient population. Linguistic
validation of the RESQ-eD in 10 languages and psychometric
properties on pooled data from these languages supports the
applicability in multinational and multilingual settings. The
RESQ-eD is available in the public domain and is free for use
in the non-commercial setting.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| Some patients with GERD experience only a partial
response of their heartburn or regurgitation symptoms
to PPI therapy.
| The presence, frequency, and severity of GERD
symptoms are best captured and measured using
PRO instruments.
| The FDA recently published its guidance for industry
on the use of PRO instruments in medical product
development to support labelling claims.
| No PRO instrument has been developed for the
speciﬁc target population of patients with GERD with
a partial response to PPI therapy.
WHAT IS NEW HERE
| The RESQ-eD was developed for use in clinical trials
in patients with a partial response to PPI therapy,
using methods that meet recent regulatory standards.
| The RESQ-eD was deemed to be valid, reliable,
and responsive to change in the clinical trial setting
in partial responders to PPI therapy.
| The RESQ-eD is, to our knowledge, the ﬁrst electronic
symptom diary designed for use in partial responders
to PPI therapy that has been developed and
documented in line with the FDA guidance on the
development and use of PRO instruments.
| The RESQ-eD is available in the public domain and
is free for use in the non-commercial setting.
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